- Pharmacological profile – trastuzumab emtansine2022 | Third Faculty of Medicine
- Trastuzumab emtansine in the treatment of residual HER2-positive breast cancer2019 | First Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: BO27938Publication without faculty affiliation
- Research Report University Hospital of the clinical trial BO27938Publication without faculty affiliation
- Experience in the treatment of advanced HER2 positive breast tumor in University Hospital in Motol2016 | Publication without faculty affiliation
- News in anti-HER2 targeted therapy in breast cancer +12013 | First Faculty of Medicine
- Trastuzumab emtansin v léčbě časného karcinomu prsu2021 | First Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BO28407Publication without faculty affiliation
- Overview of biological therapy for HER2-positive metastatic breast cancer2015 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysisPublication without faculty affiliation
- Research Report University Hospital clinical trial BO28407Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: BO28407Publication without faculty affiliation
- Complete and long-term response of HER2 positive locally highly advanced metastatic breast cancer - case report2019 | Third Faculty of Medicine
- Trastuzumab deruxtecan: strong player in the field of metastatic HER2 positive breast cancer2022 | First Faculty of Medicine
- Personalization of neo/adjuvant treatment of HER2-positive breast cancer is the key to achieve the best results2022 | First Faculty of Medicine
- Treatment of HER2-positive breast cancer in 20202020 | First Faculty of Medicine
- Skupina léků anti-HER2 pro pacientky s karcinomu prsu se rozrostla o preparát Phesgo2021 | First Faculty of Medicine
- Summary of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Prepared by the Czech Society of Cardiology2017 | Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE2021 | First Faculty of Medicine